Relevant bibliographies by topics / 35 [74.4%] survived with 18

Contents

  1. Journal articles
  2. Book chapters

Academic literature on the topic '35 [74.4%] survived with 18'

Author: Grafiati
Published: 3 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '35 [74.4%] survived with 18.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "35 [74.4%] survived with 18"

1

Bojanini Molina, Leyla, Muhamad Alhaj Moustafa, Ricardo Daniel Parrondo, et al. "Hepatosplenic T-cell lymphoma: The Mayo Clinic experience." Journal of Clinical Oncology 38, no. 15_suppl (2020): e20036-e20036. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e20036.

Full text
Abstract:
e20036 Background: Hepatosplenic T cell lymphoma (HSTL) is a rare subtype of mature T cell lymphomas accounting for less than 1 percent of non-Hodgkin lymphomas. it has been associated with poor prognosis. It typically involves sinusoids in the spleen, liver, and bone marrow. Methods: Following IRB approval, we retrospectively evaluated patients with HSTL treated at the Mayo Clinic Cancer Center 1996-2019. Kaplan-Meier survival analysis and univariate analysis to identify prognostic factors were performed. We investigated clinical characteristics and outcomes among patients with HSTL. Results:
APA, Harvard, Vancouver, ISO, and other styles
2

Dao, Vi, Morel Rubinger, Eric J. Bow, et al. "Epidemiology of Adult Acute Lymphoblastic Leukemia in Manitoba, Canada: Does This Approximate Clinical Trial Data?." Blood 106, no. 11 (2005): 4554. http://dx.doi.org/10.1182/blood.v106.11.4554.4554.

Full text
Abstract:
Abstract Background: Outcomes of unselected adult ALL patients (pts) have not been well studied at a population level. Whether such pts behave differently to those in formal clinical trials is unclear. We developed a uniform therapeutic protocol as the provincial standard of care in Manitoba, a province with 1.2 million people, for adult pts since 1989 (“ALL89-1”). The aim of this retrospective study was: to ascertain the local epidemiology of adult ALL; to analyze the efficacy and toxicity of the ALL89-1 regimen and any other regimens given to pts in a population-based setting. Methods: All p
APA, Harvard, Vancouver, ISO, and other styles
3

Blackstock, A. W., M. A. Socinski, J. Bogart, et al. "Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105." Journal of Clinical Oncology 24, no. 18_suppl (2006): 7042. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.7042.

Full text
Abstract:
7042 Background: Combined chemoradiotherapy is the standard of care in stage III NSCLC. At standard TRT doses, local failures remain problematic and strategies exploiting the dose-response aspect of TRT are warranted. 3-D TRT allows escalation of TRT dose with acceptable toxicity (Socinski et al, J Clin Oncol 22:4341, 2004) and may enhance survival by improving loco-regional control. Methods: This is a two-arm randomized phase II trial evaluating 74 Gy with Con chemotherapy: Arm A- 2 cycles of Ind carboplatin (C) (AUC 6) and paclitaxel (P) (225 mg/m2) followed by weekly Con C (AUC 2/wk) and P
APA, Harvard, Vancouver, ISO, and other styles
4

Pasini, F., G. de Manzoni, L. Stievano, et al. "Effect of neoadjuvant combined modality therapy with weekly docetaxel (D) and cisplatin (P), 5-fluorouracil (5-FU) continuous infusion (c.i.), and concurrent radiotherapy (RT) on pathological response rate in esophageal cancers (EC): A phase II study." Journal of Clinical Oncology 27, no. 15_suppl (2009): 4548. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.4548.

Full text
Abstract:
4548 Background: The achievement of pathological complete response (pCR) seems essential to improve survival in EC. In a phase I study (Pasini et al, Ann Oncol 2005) we demonstrated the feasibility of a novel protocol of neoadjuvant chemoradiation. Based on these promising results, we have performed a phase II study. The primary end point was the pathological response rate, the secondary end points were survival and toxicity. Methods: 74 pts with stage II-III EC (37 adenocarcinomas) were enrolled; median age was 59 yrs (42–73). Treatment consisted of D 35 mg/m2 and P 25 mg/m2 d 1,8,15,29,36,43
APA, Harvard, Vancouver, ISO, and other styles
5

Jabbour, Elias, Marcos De Lima, Leandro de Padua Silva, et al. "Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients (pts) with Advanced Chronic Myeloid Leukemia (CML) Post Imatinib Failure." Blood 112, no. 11 (2008): 979. http://dx.doi.org/10.1182/blood.v112.11.979.979.

Full text
Abstract:
Abstract Allogeneic HSCT is a potentially curative treatment for pts with CML, and is effective after imatinib failure. We assessed the long-term results of HSCT in 92 consecutive pts with CML that had failed imatinib. Herein are the results of this review. Preparative regimens were reduced-intensity intravenous (IV) busulfan (Bu)-fludarabine (Flu) in 40 pts, IV Bu-cyclophosphamide in 39, Flu-melphalan in 6, and total body irradiation (TBI) based regimens in 7. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and mini-methotrexate 5 mg/m2. Donors were matched related in 49
APA, Harvard, Vancouver, ISO, and other styles
6

Horiike, A., F. Ohyanagi, Y. Okano, et al. "A feasibility study of adjuvant carboplatin (C) plus gemcitabine (G) in completely resected stage IB-III non-small-cell lung cancer (NSCLC)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 18158. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.18158.

Full text
Abstract:
18158 Background: In recent randomized phase III trials in early-stage NSCLC, cisplatin-based adjuvant chemotherapy resulted in a 4.1–15% 5-year survival benefit versus observation. However, only 56–74% of patients completed planned treatment, suggestive of poor compliance. C plus G (CG), one of the standard regimens for advanced NSCLC, is considered more tolerable than other platinum-based regimens because it is associated with less nausea/vomiting, sensory neuropathy, and alopecia. The objective of this study was to assess the feasibility and safety of adjuvant CG in patients with completely
APA, Harvard, Vancouver, ISO, and other styles
7

Hügli, A., D. Moro, B. Mermillod, et al. "Phase II Trial of Up-Front Accelerated Thoracic Radiotherapy Combined With Chemotherapy and Optional Up-Front Prophylactic Cranial Irradiation in Limited Small-Cell Lung Cancer." Journal of Clinical Oncology 18, no. 8 (2000): 1662–67. http://dx.doi.org/10.1200/jco.2000.18.8.1662.

Full text
Abstract:
PURPOSE: To investigate the feasibility and outcome of bifractionated, up-front thoracic radiotherapy (TR) (45 Gy in 30 fractions of 1.5 Gy twice daily over 3 weeks) combined with chemotherapy (CT) (six cycles of cisplatin and etoposide) and optional low-dose, up-front prophylactic cranial irradiation (18 Gy in 10 fractions of 1.8 Gy twice daily over 5 days) in limited small-cell lung cancer. PATIENTS AND METHODS: CT (etoposide 100 mg/m2 for 3 days and cisplatin 25 mg/m2 for 3 days) was started on day 8 or 15 after the first TR treatment. In the five subsequent cycles, cisplatin was given as a
APA, Harvard, Vancouver, ISO, and other styles
8

Grelier, Laure, Michael Baboudjian, Bastien Gondran-Tellier, et al. "Stereotactic Body Radiotherapy for Frail Patients with Primary Renal Cell Carcinoma: Preliminary Results after 4 Years of Experience." Cancers 13, no. 13 (2021): 3129. http://dx.doi.org/10.3390/cancers13133129.

Full text
Abstract:
Introduction: The aim of this study was to report the oncological outcomes and toxicity of stereotactic body radiotherapy (SBRT) to treat primary renal cell carcinoma (RCC) in frail patients unfit for surgery or standard alternative ablative therapies. Methods: We retrospectively enrolled 23 patients who had SBRT for primary, biopsy-proven RCC at our tertiary center between October 2016 and March 2020. Treatment-related toxicities were defined using CTCAE, version 4.0. The primary outcome was local control which was defined using the Response Evaluation Criteria in Solid Tumors. Results: The m
APA, Harvard, Vancouver, ISO, and other styles
9

Socinski, Mark A., A. William Blackstock, Jeffrey A. Bogart, et al. "Randomized Phase II Trial of Induction Chemotherapy Followed by Concurrent Chemotherapy and Dose-Escalated Thoracic Conformal Radiotherapy (74 Gy) in Stage III Non–Small-Cell Lung Cancer: CALGB 30105." Journal of Clinical Oncology 26, no. 15 (2008): 2457–63. http://dx.doi.org/10.1200/jco.2007.14.7371.

Full text
Abstract:
PurposeTo evaluate 74 Gy thoracic radiation therapy (TRT) with induction and concurrent chemotherapy in stage IIIA/B non–small-cell lung cancer (NSCLC).Patients and MethodsPatients with stage IIIA/B NSCLC were randomly assigned to induction chemotherapy with either carboplatin (area under the curve [AUC], 6; days 1 and 22) with paclitaxel (225 mg/m2; days 1 and 22; arm A) or carboplatin (AUC, 5; days 1 and 22) with gemcitabine (1,000 mg/m2; days 1, 8, 22, and 29; arm B). On day 43, arm A received weekly carboplatin (AUC, 2) and paclitaxel (45 mg/m2) while arm B received biweekly gemcitabine (3
APA, Harvard, Vancouver, ISO, and other styles
10

Proctor, Stephen J., Jennifer Wilkinson, Gail Jones, et al. "Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study." Blood 119, no. 25 (2012): 6005–15. http://dx.doi.org/10.1182/blood-2011-12-396556.

Full text
Abstract:
Abstract The SHIELD program for Hodgkin lymphoma in patients 60 years of age or older, prospectively evaluated clinical features and outcome in a large patient cohort (n = 175). The central element was a phase 2 study of VEPEMB chemotherapy (n = 103, median age 73 years) incorporating comorbidity assessment. A total of 72 other patients were treated off-study but registered prospectively and treated concurrently with: ABVD (n = 35); CLVPP (n = 19), or other (n = 18). Of VEPEMB patients, 31 had early-stage disease (stage 1A/2A) and received VEPEMB 3 times plus radiotherapy. Median follow-up was
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "35 [74.4%] survived with 18"

1

"Mars, G. 55 testing of researcher in 125–6; value Mason, J. 63 of work in 124–6 Maynard, M. 32, 101 Meerabeau, L. 100 Oakley, A. 15, 94, 97 methodologies: autobiography 21; Okely, J. 94, 96; and Callaway, H. 96 collective memory 21; covert Opie, A. 101 17–18, 46–7, 56, 164, 169–70, Owens, D. 100 198–9; desk work/fieldwork balance 57; disengagement 122; Parker, C. 134, 135, 138 formal interviews 170; in-depth Patrick, J. 58 interviews 117; interest in 92–3; Payne, G. et al. 92 non-participant 117; participant Pearson, G. 35, 64 observation 21, 34–6, 39, 137–40, Peritore, N.P. 28 142–4, 170–1; physical danger 3, 8–9, 43, 61–2, 132, qualitative/quantitative 13, 14, 21, 147, 203; in communities under 23, 61–2, 87, 115, 117, 129–30, threat 11; experience of 74–81; and 147, 149; reflexive 12, 16, 56–7, extremism 156, 163; gender 89, 114, 116, 143, 144; symbolic 20 dynamics of 12; and health 11–12; Milgram, S. 17 intimidation/destabilisation 137; Morgan, D. 18, 38, 57 negotiation of 67–8; and Morris, S. 45 participant-observer role 137–40; Mungham, G. 50 participant/researcher sharing of Mykhalovskiy, E. 108 12–13; personal 11–12; preparation for/anticipation of 69–70, 72; National Front 56 reduction in 62–3; at religious New Religious Movements (NRMs) festival 137–42; on the streets 148, 150, 153, 154, 162, 163 10–11; threat of 68; vs psychological New Reproductive Technologies 184–6; and vulnerability of (NRTs) 92 researcher 63–4 nursing home 114–15; as policing 26–7, 40–1; and bouncers 48, alien/unsettling 118; 49, 51; and cult of masculinity 31; contamination/escape from 126–7; danger 26, 27–9, 32; and danger emotional strains in 123–4; initial from above 37–9; enduring emotional responses to 118–23; fieldwork in 29–32; and fear 32, membership issues 119–23; negative 33–7; and gender identity 26, 27, feelings for 126–7; punishment 28, 33–4, 40; and group solidarity strategies 121–2; researcher/staff 27; insider/outsider relationship interaction 119–20; setting of 117; 27–8, 35, 38, 40; and local staff/patient interaction 119, population 34–6; and protectiveness 121–2, 125; structure of 118; and 28–9, 36; research sites 27; seeing." In Danger in the Field. Routledge, 2002. http://dx.doi.org/10.4324/9780203136119-40.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

"Gane, Mike 77–80, 84, 98 Le Moyne, Gertrude 119 Gariépy, Renault 59 Lévesque, René 105–6 Garric, Daniel 5, 58, 62 Levin, Charles 2, 66 Gates, Bill 13 Lévi-Strauss, Claude 6, 19, 22–5 de Gaulle, Charles 46, 100 Lewis, Wyndham 55–6 Genosko, Gary 55, 67, 110 Libermann, Ben 84 Gheerbrand, Gilles 62 Lukács, Georg 113–15 Gibson, Steve 11 Lyotard, Jean-François 49–51, 69, 110 Giradin, Jean-Claude 81 Giscard d’Estaing, Valéry 46, 103 Gould, Glenn 10, 17 McLughan, William 53 Grant, George 70 McLuhan, Corinne 9 Grigg, Russell 54 McLuhan, Eric 9 Gritti, Jules 74–5 Mandel, Ernest 111 Grock, Adrian Wettach 36, 50 Marabini, Jean 5, 58–9 Guattari, Félix 7, 17, 48–50, 105, Marchand, Philip 15, 62 110–11 Marcotte, Gilles 58, 119 Mariet, François 61–2 Marx, Karl 24, 69, 111–16 Hall, Stuart 31 Matson, Raymer B. 104 Halley, Peter 3 Mattelart, Armand 45–6 Heath, Stephen 56 Mattelart, Michèle 45 Hjelmslev, Louis 48–50 Metz, Christian 50 Hoggart, Richard 6, 17, 31–4 Michelet, Jules 21 Holland, Eugene 55 Miller, Jonathan 28, 109 Hurtubise, Claude 5 Missika, Jean-Louis 47 Huyssen, Andreas 4, 13 Molinaro, Matie 9 Monnier-Raball, Jacques 72 Iannone, M. 13 Monroe, Marilyn 59 Ionesco, Eugène 30, 57 Morin, Edgar 41–2 Moriwaki, Hiroyuki 10 Jameson, Fredric 65, 112–14 Jarry, Alfred 55 Nadeau, Maurice 18 Namer, Gérard 44 Negri, Antonio 105 Kattan, Naïm 4–5, 18 Nixon, Richard 3 Kellner, Douglas 67, 77, 84–5, 98 de Kerckhove, Derrick 9–10, 14–15, 30–1, 35, 43, 87, 119–21 Ong, Walter J. 56 Klein, Calvin 65 Orlan 11 Knockaert, Yves 58 Kroker, Arthur 2–3, 8–9, 11–12, 22, Paglia, Camille 1 28–9, 64–70, 115 Paik, Nam June 10, 30 Kroker, Marilouise 11 Paré, Jean 5–6, 22, 92, 99–103, 105 Parker, Harley 34, 81, 118 Lacan, Jacques 7, 52–4, 56–7, 63 Pasolini, Pier Paolo 104 Languirand, Jacques 103 Passeron, Jean-Claude 17 Lanoux, Armand 58–9 Paterson, Nancy 10 Lazarsfeld, Paul 50 Pauwels, Louis 120–1." In McLuhan and Baudrillard. Routledge, 2002. http://dx.doi.org/10.4324/9780203005217-15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic '35 [74.4%] survived with 18' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography